Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Halozyme Therapeutics Inc HALO

Healthcare Biotechnology
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on... see more

Recent & Breaking News (NDAQ:HALO)

Halozyme Announces Broad Clinical Collaboration Agreement To Evaluate PEGPH20 And Tecentriq In Up To Eight Tumor Types

PR Newswire November 10, 2016

Halozyme Reports Third Quarter 2016 Financial Results

PR Newswire November 7, 2016

Watch These 5 Huge Call Purchases In Friday Trade

Benzinga.com  November 4, 2016

FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab

PR Newswire November 3, 2016

Watch These 5 Huge Put Purchases In Monday Trade

Benzinga.com  October 17, 2016

Halozyme To Host Third Quarter 2016 Financial Results Conference Call

PR Newswire October 13, 2016

Research Report Coverage on Biotech Stocks -- Halozyme Therapeutics, Achillion Pharma, Aegerion Pharma and Chimerix

PR Newswire August 23, 2016

Halozyme Announces Agreement To Refinance Debt, Increases 2016 Guidance For Year-End Cash Balance

PR Newswire June 8, 2016

Mid-Morning Market Update: Markets Open Higher; Devon Energy To Sell Non-Core Upstream Assets For Around $1 Billion

Benzinga.com  June 6, 2016

Halozyme Therapeutics To Present At The UBS 2016 Global Health Care Conference

PR Newswire May 17, 2016

Halozyme Reports First Quarter 2016 Financial Results

PR Newswire May 9, 2016

Halozyme to Host First Quarter 2016 Financial Results Conference Call

PR Newswire April 20, 2016

Halozyme Expands Oncology Pipeline With Two Compounds Designed For Activity In The Tumor Microenvironment

PR Newswire April 18, 2016

Halozyme To Present Data From Five Preclinical Studies At American Association Of Cancer Research Annual Conference

PR Newswire March 17, 2016

Halozyme Doses First Patient In Phase 3 Clinical Trial Of PEGPH20 In Combination With ABRAXANE® And Gemcitabine

PR Newswire March 16, 2016

Halozyme Appoints Jim Daly To Board Of Directors

PR Newswire March 7, 2016

Halozyme Therapeutics To Present At Upcoming Healthcare Conferences

PR Newswire March 2, 2016

Halozyme Reports Fourth Quarter And Full Year 2015 Financial Results

PR Newswire February 29, 2016

Halozyme To Host Fourth Quarter And 2015 Year-End Financial Results Conference Call

PR Newswire February 1, 2016

Halozyme Announces Closing Of $150 Million Royalty-Backed Debt Financing

PR Newswire January 26, 2016